Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regenerative Medical Technology (RMTG) Equity Average (2018 - 2025)

Historic Equity Average for Regenerative Medical Technology (RMTG) over the last 8 years, with Q3 2025 value amounting to -$29.5 million.

  • Regenerative Medical Technology's Equity Average fell 1241.46% to -$29.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$29.5 million, marking a year-over-year decrease of 1241.46%. This contributed to the annual value of -$24.6 million for FY2024, which is 4551.62% down from last year.
  • Per Regenerative Medical Technology's latest filing, its Equity Average stood at -$29.5 million for Q3 2025, which was down 1241.46% from -$28.6 million recorded in Q2 2025.
  • Over the past 5 years, Regenerative Medical Technology's Equity Average peaked at -$1.1 million during Q3 2021, and registered a low of -$29.5 million during Q3 2025.
  • For the 5-year period, Regenerative Medical Technology's Equity Average averaged around -$16.2 million, with its median value being -$14.7 million (2023).
  • Its Equity Average has fluctuated over the past 5 years, first skyrocketed by 9275.5% in 2021, then tumbled by 83537.09% in 2022.
  • Over the past 5 years, Regenerative Medical Technology's Equity Average (Quarter) stood at -$6.1 million in 2021, then tumbled by 87.37% to -$11.5 million in 2022, then crashed by 88.56% to -$21.7 million in 2023, then fell by 24.78% to -$27.0 million in 2024, then dropped by 9.25% to -$29.5 million in 2025.
  • Its Equity Average stands at -$29.5 million for Q3 2025, versus -$28.6 million for Q2 2025 and -$27.7 million for Q1 2025.